AHA 2022: Sotagliflozin, a Dual SGLT-1/2 Inhibitor, Modulated Expression of Endothelial Proteins That Inhibit Reactive Oxygen Species During Inflammation Compared With Empagliflozin

373 views
November 16, 2022
0 Comments
Login to view comments. Click here to Login